Néovacs Showcases Its mRNA Platform and Innovative Lipids at Bpifrance
Néovacs participated in the second French meeting on lipid nanoparticles (LNP) for mRNA delivery, held on April 10, 2026, at Bpifrance. The biopharmaceutical company presented its mRNA platform and its work on new innovative lipids.
An mRNA Platform for Inflammatory Diseases
Néovacs introduced its mRNA technological platform developed for the treatment of chronic inflammatory diseases, including allergies. The company also showcased its efforts in designing new innovative lipids aimed at mRNA delivery. This event, organized by Dr. Mignet (Université Paris Cité, CNRS) in collaboration with Néovacs represented by Dr. Lemdani (Director of R&D), brought together academic researchers, industry professionals, and innovation stakeholders to discuss the scientific and translational challenges of LNP/mRNA.
Prominence in the French Health Ecosystem
For the second consecutive year, Néovacs participated in organizing this meeting, which took place with the support of the French Society of Nanomedicine (SFNano). The diversity of expertise present and the quality of the discussions confirmed the dynamism of the French community in the LNP/mRNA field. This event highlights Néovacs' role in the French health excellence ecosystem and the innovative strength of the sector in RNA-based therapies.
